An insider purchase at LENZ Therapeutics, Inc. (NASDAQ: LENZ) was disclosed for March 27, 2026. Director George Jeffrey P. acquired 5,592 shares of common stock in a transaction valued at $49,890. The shares were bought at a weighted average price of $8.92, within a reported price range from $8.80 to $9.12.
The timing of the purchase followed a sharp move in the stock. LENZ shares fell 24% over the prior week and were trading around $8.40, a level that is close to the company’s 52-week low of $8.39.
According to InvestingPro analysis cited with the transaction details, LENZ appears to be priced below its estimated intrinsic value. InvestingPro assigns a Fair Value of $13.80 to LENZ, implying potential upside relative to prevailing market prices at the time of the trade.
After completing the purchase, George Jeffrey P. directly holds 5,592 shares of LENZ Therapeutics common stock.
InvestingPro also provides supplemental research tools for the company, including 12 additional ProTips and a comprehensive Pro Research Report that covers LENZ alongside more than 1,400 other U.S. listed equities.
Separately, LENZ’s most recent financial update covered the company’s full-year period ending with Q4 2025. The filing and accompanying commentary highlighted a strong cash position and the company’s first revenue related to its presbyopia treatment, VIZZ. The report also disclosed a substantial quarterly net loss, which management attributed primarily to higher operating expenses.
LENZ initiated formal commercialization of VIZZ in October 2025. Broader availability and distribution of the product became more evident by the middle of the fourth quarter. Because commercialization began late in the year, year-end financials reflect less than one full quarter of product adoption and therefore represent very early-stage market penetration for VIZZ.
Market analysts have taken note of the commercialization phase. H.C. Wainwright reiterated a Buy rating on LENZ and set a $56.00 price target, explicitly noting the importance of the VIZZ commercialization rollout in its assessment. The firm’s commentary was presented as part of a cautious but optimistic analyst view despite the company’s recent quarterly loss.
The combined disclosures - the director purchase, InvestingPro’s Fair Value estimate, the Q4 2025 financials showing both early revenue and a substantial net loss, and H.C. Wainwright’s reiterated Buy rating with a $56.00 target - provide a snapshot of LENZ at a moment when commercialization is nascent and financial performance is still being shaped by elevated operating costs.